Global Information
회사소개 | 문의 | 위시리스트

백반증 : 역학 예측(-2028년)

Vitiligo - Epidemiology Forecast - 2028

리서치사 DelveInsight Business Research LLP
발행일 2019년 08월 상품 코드 524480
페이지 정보 영문 92 Pages
가격
US $ 3,250 ₩ 3,901,000 PDF by E-mail (Single User License)
US $ 6,500 ₩ 7,803,000 PDF by E-mail (Site License)
US $ 9,750 ₩ 11,704,000 PDF by E-mail (Global License)


백반증 : 역학 예측(-2028년) Vitiligo - Epidemiology Forecast - 2028
발행일 : 2019년 08월 페이지 정보 : 영문 92 Pages

주요 7개국(미국, 영국, 독일, 프랑스, 이탈리아, 스페인, 일본)의 백반증 유병자수는 2017년에 623만 4,655명으로 추산됩니다. 7개국을 비교하면 미국의 유병자수가 가장 많아지고 있습니다.

주요 7개국(미국, 영국, 독일, 프랑스, 이탈리아, 스페인, 일본)의 백반증(Vitiligo) 시장을 조사했으며, 시장 개요, 종류별·연령별·성별 유병수 추정과 예측, 질병 배경, 국가별 상세 동향 등을 정리했습니다.

목차

제1장 주요 인사이트

제2장 백반증 : 환자 개요

  • 환자 분포(실수치)
  • 환자 분포(예측치)

제3장 질병 배경과 개요

  • 서론
  • 백반증 종류
  • 원인
  • 증상
  • 병태생리
  • 유전학
  • 진단
    • 진단 가이드라인

제4장 역학과 환자 인구

  • 주요 조사 결과
  • 인구와 예측 파라미터
  • 주요 7개국의 유병자수

제5장 미국의 백반증 역학

  • 가정과 근거
  • 유병수
  • 유병수 : 성별
  • 진단수
  • 진단 유병수 : 종류별
  • 유병수 : 연령별

제6장 유럽 5개국의 백반증 역학

  • 가정과 근거
  • 독일
    • 가정과 근거
    • 유병수
    • 유병수 : 성별
    • 진단수
    • 진단 유병수 : 종류별
    • 유병수 : 연령별
  • 프랑스
    • 가정과 근거
    • 유병수
    • 유병수 : 성별
    • 진단수
    • 진단 유병수 : 종류별
    • 유병수 : 연령별
  • 이탈리아
    • 가정과 근거
    • 유병수
    • 유병수 : 성별
    • 진단수
    • 진단 유병수 : 종류별
    • 유병수 : 연령별
  • 스페인
    • 가정과 근거
    • 유병수
    • 유병수 : 성별
    • 진단수
    • 진단 유병수 : 종류별
    • 유병수 : 연령별
  • 영국
    • 가정과 근거
    • 유병수
    • 유병수 : 성별
    • 진단수
    • 진단 유병수 : 종류별
    • 유병수 : 연령별

제7장 일본의 백반증 역학

  • 가정과 근거
  • 유병수
  • 유병수 : 성별
  • 진단수
  • 진단 유병수 : 종류별
  • 유병수 : 연령별

제8장 부록

  • 보고 방법

제9장 출전

제10장 DelveInsight의 서비스 내용

제11장 면책사항

제12장 DelveInsight 소개

KSM 19.08.16

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Table 1 Fitzpatrick skin types classification
  • Table 2 Levels of evidence (from Scottish Inter-Collegiate Guidelines Network)
  • Table 3 Grades of recommendation (from Scottish Inter-Collegiate Guidelines Network)
  • Table 4 Criteria for levels of evidence and grades of recommendation
  • Table 5 Total Prevalent Population of Vitiligo in 7MM (2017-2028)
  • Table 6 Prevalent Population of Vitiligo in the United States (2017-2028)
  • Table 7 Gender-Specific Prevalent Population of Vitiligo in the United States (2017-2028)
  • Table 8 Diagnosed cases of Vitiligo in the United States (2017-2028)
  • Table 9 Type-Specific Diagnosed Prevalent cases of Vitiligo in the United States (2017-2028)
  • Table 10 Age-Specific Prevalent cases of Vitiligo in the United States (2018)
  • Table 11 Prevalent Population of Vitiligo in Germany (2017-2028)
  • Table 12 Gender-Specific Prevalent Population of Vitiligo in Germany (2017-2028)
  • Table 13 Diagnosed cases of Vitiligo in Germany (2017-2028)
  • Table 14 Type-Specific Diagnosed Prevalent cases of Vitiligo in Germany (2017-2028)
  • Table 15 Age-Specific Prevalent cases of Vitiligo in Germany (2018)
  • Table 16 Prevalent Population of Vitiligo in France (2017-2028)
  • Table 17 Gender-Specific Prevalent Population of Vitiligo in France (2017-2028)
  • Table 18 Diagnosed cases of Vitiligo in the France (2017-2028)
  • Table 19 Type-Specific Diagnosed Prevalent cases of Vitiligo in France (2017-2028)
  • Table 20 Age-Specific Prevalent cases of Vitiligo in France (2018)
  • Table 21 Prevalent Population of Vitiligo in Italy (2017-2028)
  • Table 22 Gender-Specific Prevalent Population of Vitiligo in Italy (2017-2028)
  • Table 23 Diagnosed cases of Vitiligo in Italy (2017-2028)
  • Table 24 Type-Specific Diagnosed Prevalent cases of Vitiligo in Italy (2017-2028)
  • Table 25 Age-Specific Prevalent cases of Vitiligo in Italy (2018)
  • Table 26 Prevalent Population of Vitiligo in Spain (2017-2028)
  • Table 27 Gender-Specific Prevalent Population of Vitiligo in Spain (2017-2028)
  • Table 28 Diagnosed cases of Vitiligo in Spain (2017-2028)
  • Table 29 Type-Specific Diagnosed Prevalent cases of Vitiligo in Spain (2017-2028)
  • Table 30 Age-Specific Prevalent cases of Vitiligo in Spain (2018)
  • Table 31 Prevalent Population of Vitiligo in the United Kingdom (2017-2028)
  • Table 32 Gender-Specific Prevalent Population of Vitiligo in the United Kingdom (2017-2028)
  • Table 33 Diagnosed cases of Vitiligo in the UK (2017-2028)
  • Table 34 Type-Specific Diagnosed Prevalent cases of Vitiligo in the United Kingdom (2017-2028)
  • Table 35 Age-Specific Prevalent cases of Vitiligo in the UK (2018)
  • Table 36 Prevalent Population of Vitiligo in Japan (2017-2028)
  • Table 37 Gender-Specific Prevalent Population of Vitiligo in Japan (2017-2028)
  • Table 38 Diagnosed cases of Vitiligo in Japan (2017-2028)
  • Table 39 Type-Specific Diagnosed Prevalent cases of Vitiligo in Japan (2017-2028)
  • Table 40 Age-Specific Prevalent cases of Vitiligo in Japan (2018)

List of Figures

  • Figure 1 Types of Vitiligo
  • Figure 2 Type of Non-segmental Vitiligo
  • Figure 3 Symptoms of Vitiligo
  • Figure 4 Cellular and Humoral immune mechanisms of Vitiligo
  • Figure 5 Pathogenesis of Vitiligo
  • Figure 6 Identification of Vitiligo susceptibility genes
  • Figure 7 Total Prevalent Population of Vitiligo in the 7 MM (2017-2028)
  • Figure 8 Prevalent Population of Vitiligo in the United States (2017-2028)
  • Figure 9 Gender-Specific Prevalent Population of Vitiligo in the United States (2017-2028)
  • Figure 10 Diagnosed cases of Vitiligo in the United States (2017-2028)
  • Figure 11 Type-Specific Diagnosed Prevalent cases of Vitiligo in the United States (2017-2028)
  • Figure 12 Age-Specific Prevalent cases of Vitiligo in the United States (2018)
  • Figure 13 Prevalent Population of Vitiligo in Germany (2017-2028)
  • Figure 14 Gender-Specific Prevalent Population of Vitiligo in Germany (2017-2028)
  • Figure 15 Diagnosed cases of Vitiligo in Germany (2017-2028)
  • Figure 16 Type-Specific Diagnosed Prevalent cases of Vitiligo in Germany (2017-2028)
  • Figure 17 Age-Specific Prevalent cases of Vitiligo in Germany (2018)
  • Figure 18 Prevalent Population of Vitiligo in France (2017-2028)
  • Figure 19 Gender-Specific Prevalent Population of Vitiligo in France (2017-2028)
  • Figure 20 Diagnosed cases of Vitiligo in France (2017-2028)
  • Figure 21 Type-Specific Diagnosed Prevalent cases of Vitiligo in France (2017-2028)
  • Figure 22 Age-Specific Prevalent cases of Vitiligo in France (2018)
  • Figure 23 Prevalent Population of Vitiligo in Italy (2017-2028)
  • Figure 24 Gender-Specific Prevalent Population of Vitiligo in Italy (2017-2028)
  • Figure 25 Diagnosed cases of Vitiligo in Italy (2017-2028)
  • Figure 26 Type-Specific Diagnosed Prevalent cases of Vitiligo in Italy (2017-2028)
  • Figure 27 Age-Specific Prevalent cases of Vitiligo in Italy (2018)
  • Figure 28 Prevalent Population of Vitiligo in Spain (2017-2028)
  • Figure 29 Gender-Specific Prevalent Population of Vitiligo in Spain (2017-2028)
  • Figure 30 Diagnosed cases of Vitiligo in Spain (2017-2028)
  • Figure 31 Type-Specific Diagnosed Prevalent cases of Vitiligo in Spain (2017-2028)
  • Figure 32 Age-Specific Prevalent cases of Vitiligo in Spain (2018)
  • Figure 33 Prevalent Population of Vitiligo in the United Kingdom (2017-2028)
  • Figure 34 Gender-Specific Prevalent Population of Vitiligo in the United Kingdom (2017-2028)
  • Figure 35 Diagnosed cases of Vitiligo in the UK (2017-2028)
  • Figure 36 Type-Specific Diagnosed Prevalent cases of Vitiligo in the United Kingdom (2017-2028)
  • Figure 37 Age-Specific Prevalent cases of Vitiligo in the UK (2018)
  • Figure 38 Prevalent Population of Vitiligo in Japan (2017-2028)
  • Figure 39 Gender-Specific Prevalent Population of Vitiligo in Japan (2017-2028)
  • Figure 40 Diagnosed cases of Vitiligo in Japan (2017-2028)
  • Figure 41 Type-Specific Diagnosed Prevalent cases of Vitiligo in Japan (2017-2028)
  • Figure 42 Age-Specific Prevalent cases of Vitiligo in Japan (2018)

DelveInsight's 'Vitiligo - Epidemiology Forecast-2028' report deliver an in-depth understanding of the disease, historical & forecasted epidemiology of Vitiligo in the United States, EU5 (Germany, Spain, Italy, France and the United Kingdom), and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2028

Vitiligo - Disease Understanding

The American Vitiligo Research foundation defines Vitiligo as a condition in which the skin loses melanin, the pigment that determines the color of skin, hair, and eyes. If the cells that do not produce melanin die or no longer produce melanin, slowing growing white patches of irregular shapes appear on the skin. The typical lesions on the skin can be defined as milky white, non-scaly macules that are present with distinct margins. Vitiligo can also affect the mucous membranes, including tissues inside the mouth and nose. It can affect people of all skin types but is generally noticeable much in darker-skinned people.

Researchers have identified several forms of Vitiligo. Generalized Vitiligo (also called non-segmental Vitiligo), which is the most common form, involves loss of pigment (depigmentation) in patches of skin all over the body. Depigmentation typically occurs on the face, neck, and scalp, and around body openings such as the mouth and genitals. Sometimes pigment is lost in mucous membranes, such as the lips. Loss of pigmentation is also frequently seen in areas that tend to experience rubbing, impact, or other trauma, such as the hands, arms, and places where bones are close to the skin surface (bony prominences).

Another form called segmental Vitiligo (also known as unilateral or localised Vitiligo) is associated with smaller patches of depigmented skin that appear on one side of the body in a limited area; this occurs in about 10% of affected individuals. In segmental Vitiligo, the white patches only affect one area of the body. Segmental Vitiligo is less common than non-segmental Vitiligo, although it's more common in children.

The DelveInsight Vitiligo epidemiology report gives a thorough understanding of the Vitiligo by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends.

Vitiligo

The Vitiligo epidemiology division provide insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Prevalence of Vitiligo in 7MM, Total Diagnosed Prevalence of Vitiligo in 7MM, Gender-specific Prevalence of Vitiligo in 7MM, Age-specific Diagnosed Prevalence of Vitiligo in 7MM, and Type-specific Diagnosed Prevalence of Vitiligo in 7MM) scenario of Vitiligo in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

According to DelveInsight, the total number of prevalent population of Vitiligo was found to be 6,234,655 in 7MM in the year 2017. Also suggests the United States showed the highest number of cases with Vitiligo, as compared to other 7MM countries.

Among the European countries, Germany has the highest prevalent population with 472,057 cases followed by the United Kingdom which has prevalent population of 290,965 in 2017. DelveInsight's epidemiology model suggests that overall, female population was found to be more prevalent than male population. Based on the type of Vitiligo, non-segmental Vitiligo was found to be more prevalent, across the 7MM countries.

Report Scope

  • The report covers a descriptive overview of the Vitiligo, explaining its causes, risk factors, pathophysiology and currently available therapies.
  • Comprehensive insight has been provided into the epidemiology of Vitiligo in the 7MM countries covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • Assesses growth opportunities in the 7MM countries with respect to the patient population.

Key strengths

  • 10 Year Forecast
  • 7MM countries
  • Total Patient Pool of Vitiligo
  • Type-specific Patient Pool of Vitiligo

Key assessments

  • Patient Segmentation
  • Disease Risk & Burden
  • Type-specific cases of Vitiligo

Table of Contents

1. Key Insights

2. Vitiligo: Patient Overview at a Glance

  • 2.1. Patient Share (%) Distribution of Vitiligo in 2017
  • 2.2. Patient Share (%) Distribution of Vitiligo in 2028

3. Disease Background and Overview: Vitiligo

  • 3.1. Introduction
  • 3.2. Types of Vitiligo
  • 3.3. Causes of Vitiligo
  • 3.4. Symptoms of Vitiligo
  • 3.5. Pathophysiology
  • 3.6. Genetics of Vitiligo
  • 3.7. Diagnosis
    • 3.7.1. Diagnostic Guidelines

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Population and Forecast Parameters
  • 4.3. Prevalent Population of Vitiligo in 7MM

5. United States-Epidemiology of Vitiligo

  • 5.1. Assumptions and Rationale
  • 5.2. Prevalent Population of Vitiligo in the United States
  • 5.3. Gender-Specific Prevalent Population of Vitiligo in the United States
  • 5.4. Diagnosed Cases of Vitiligo in the United States
  • 5.5. Type-Specific Diagnosed Prevalent cases of Vitiligo in the United States
  • 5.6. Age-Specific Prevalent cases of Vitiligo in the United States

6. EU-5 Epidemiology of Vitiligo

  • 6.1. Assumptions and Rationale
  • 6.2. Germany
    • 6.2.1. Prevalent Population of Vitiligo in Germany
    • 6.2.2. Gender-Specific Prevalent Population of Vitiligo in Germany
    • 6.2.3. Diagnosed Cases of Vitiligo in Germany
    • 6.2.4. Type-Specific Diagnosed Prevalent cases of Vitiligo in Germany
    • 6.2.5. Age-Specific Prevalent cases of Vitiligo in Germany
  • 6.3. France
    • 6.3.1. Prevalent Population of Vitiligo in France
    • 6.3.2. Gender-Specific Prevalent Population of Vitiligo in France
    • 6.3.3. Diagnosed Cases of Vitiligo in France
    • 6.3.4. Type-Specific Diagnosed Prevalent cases of Vitiligo in France
    • 6.3.5. Age-Specific Prevalent cases of Vitiligo in France
  • 6.4. Italy
    • 6.4.1. Prevalent Population of Vitiligo in Italy
    • 6.4.2. Gender-Specific Prevalent Population of Vitiligo in Italy
    • 6.4.3. Diagnosed Cases of Vitiligo in Italy
    • 6.4.4. Type-Specific Diagnosed Prevalent cases of Vitiligo in Italy
    • 6.4.5. Age-Specific Prevalent cases of Vitiligo in Italy
  • 6.5. Spain
    • 6.5.1. Prevalent Population of Vitiligo in Spain
    • 6.5.2. Gender-Specific Prevalent Population of Vitiligo in Spain
    • 6.5.3. Diagnosed Cases of Vitiligo in Spain
    • 6.5.4. Type-Specific Diagnosed Prevalent cases of Vitiligo in Spain
    • 6.5.5. Age-Specific Prevalent cases of Vitiligo in Spain
  • 6.6. United Kingdom
    • 6.6.1. Prevalent Population of Vitiligo in the United Kingdom
    • 6.6.2. Gender-Specific Prevalent Population of Vitiligo in the United Kingdom
    • 6.6.3. Diagnosed Cases of Vitiligo in the United Kingdom
    • 6.6.4. Type-Specific Diagnosed Prevalent cases of Vitiligo in the United Kingdom
    • 6.6.5. Age-Specific Prevalent cases of Vitiligo in the United Kingdom

7. Japan-Epidemiology of Vitiligo

  • 7.1. Assumptions and Rationale
  • 7.2. Prevalent Population of Vitiligo in Japan
  • 7.3. Gender-Specific Prevalent Population of Vitiligo in Japan
  • 7.4. Diagnosed Cases of Vitiligo in Japan
  • 7.5. Type-Specific Diagnosed Prevalent cases of Vitiligo in Japan
  • 7.6. Age-Specific Prevalent cases of Vitiligo in Japan

8. Appendix

  • 8.1. Report Methodology

9. Sources Used

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

Back to Top
전화 문의
F A Q